Skip Navigation


JAC Advance Access originally published online on November 19, 2008
Journal of Antimicrobial Chemotherapy 2009 63(2):246-251; doi:10.1093/jac/dkn469
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
63/2/246    most recent
dkn469v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Leibovici, L.
Right arrow Articles by Paul, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leibovici, L.
Right arrow Articles by Paul, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Review

Aminoglycoside drugs in clinical practice: an evidence-based approach

Leonard Leibovici1,2,*, Liat Vidal1,2 and Mical Paul1,2,3

1 Department of Medicine E, Beilinson Campus, Petah-Tiqva 49100, Israel 2 Sackler Faculty of Medicine, Tel-Aviv University, Ramat-Aviv, Tel-Aviv, Israel 3 The Infectious Diseases Unit, Beilinson Campus, Rabin Medical Center, Petah-Tiqva 49100, Israel

* Corresponding author. Tel: +972-3-9376501; Fax: +972-3-9376512; E-mail: leibovic{at}post.tau.ac.il

Resistant bacteria have renewed our interest in the aminoglycoside drugs. Evidence on the efficiency of aminoglycosides in their different clinical uses is available from numerous randomized controlled trials and has been accrued and examined in recent systematic reviews and meta-analyses. Their results show that aminoglycosides should not be added to broad-spectrum β-lactams to achieve synergism in treating Gram-negative infections as combination does not improve efficacy and adds side effects. The evidence from randomized trials in humans does not support the use of aminoglycosides in staphylococcal or streptococcal endocarditis, and is lacking for endocarditis caused by enterococci. Aminoglycosides are efficacious and safe as single drugs for the treatment of pyelonephritis and sepsis of a urinary source, but their efficacy might be lower than that of β-lactams in Gram-negative infections of other sources. In patients with no risk factors, aminoglycosides are as safe as β-lactams regarding side effects. They probably induce less resistance. Pragmatic large trials are needed to answer open clinical questions on the use of aminoglycosides.

Keywords: aminoglycosides , synergism , β-lactams , evidence-based medicine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
E. E. Keuleyan and K. G. Kirilov
Comment on: Aminoglycoside drugs in clinical practice: an evidence-based approach
J. Antimicrob. Chemother., May 1, 2009; 63(5): 1081 - 1082.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
L. Leibovici, L. Vidal, and M. Paul
Aminoglycoside drugs in clinical practice: an evidence-based approach--authors' response
J. Antimicrob. Chemother., May 1, 2009; 63(5): 1082 - 1083.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.